Article | June 22, 2023

How Lipid Nanoparticle (LNP) Technology Meets The Delivery Need Of Breakthrough saRNA Vaccine

Doctor Preparing Injection Site GettyImages-1379313214

RNA vaccines are hugely versatile. They can potentially inoculate against any pathogen for which a protein target is known. Self-amplifying RNA (saRNA) maintains the advantages of mRNA vaccines but requires a lower dose of RNA due to its self-replicative properties. This reduces the burden of manufacturing, allowing facilities to make 100x more doses than with mRNA due to the reduced cost and time required. As a result, distributed/decentralized manufacturing and quick mass immunizations are possible in the event of a pandemic.

Explore challenges to the successful development of RNA-based drugs and vaccines as well as the advantages of utilizing lipid nanoparticle technology as a delivery platform for saRNA.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene